Gilead Sciences, Inc. (GILD): This Biotech Leader Is Poised to Outperform

Page 1 of 2

Investing in biotech companies can be risky; developing new drugs is a long, expensive, and uncertain process, and there is always considerable regulatory risk in the industry. When it comes to Gilead Sciences, Inc. (NASDAQ:GILD), however, its dominant position in HIV treatment and the company’s growth prospects make it look like a long term winner.

Leadership

Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) is the undisputed leader in HIV treatments; the company makes more than 75% of its revenue from different drugs to fight the disease. Viread, Emtriva, and combo drug Truvada have been the key growth drivers for Gilead over the last years, but the all-in-one triple combination pill, Atripla, has been the most recent winner, and it now generates more than 30% of the company´s revenues.

Atripla combines Gilead Sciences, Inc. (NASDAQ:GILD)´s Truvada with Bristol Myers Squibb Co. (NYSE:BMY)’s Sustiva, and it’s the first pill approved by the FDA as a one single pill for HIV treatment. By providing a much simpler treatment, Atripla has material positive effects on patient compliance, which is a key factor when it comes to effectiveness in treatments. Besides, it makes the treatment more affordable.

Truvada, which has traditionally been used for HIV treatment, recently received approval from the FDA to be used as the first HIV prevention drug. This has raised some controversy among experts, but it has the potential to be a real game changer. The drug is approved for uninfected people who are at high risk of contracting HIV thorough sex, these include sex workers and people with partners who are HIV-positive or engage in high-risk behaviors, such as using IV drugs.

In the middle term, Stribilid is showing promising potential. This all-Gilead regimen containing a new integrase inhibitor entered the market in 2012, and it could lead Gilead Sciences, Inc. (NASDAQ:GILD) into the next phase of growth in HIV treatment. Stribilid will be facing strong competition from Merck & Co., Inc. (NYSE:MRK)´s well established drug Isentress which generated sales of 1.5 billion for the company in 2012, an increase of 11% versus 2011.

Although Merck has the leadership position in this segment, Gilead´s competitive strength in HIV treatment should not be underestimated, especially considering that Stribilid is off to an auspicating start.

Growth prospects

Speaking at the UBS Global Healthcare Conference in May of this year, Gilead´s management said that the company currently has the biggest amount of products in Phase 3 studies in its history. Not only when it comes to HIV treatment, but also for cardiovascular, respiratory, and oncology diseases, Gilead Sciences, Inc. (NASDAQ:GILD) has a promising pipeline.

Source Gilead investor fact sheet

One particularly exciting opportunity for the company is hepatitis-C treatment, and Gilead´s sofosbuvir drug has some very real chances at becoming a blockbuster in a gigantic market.

According to the company, the global prevalence of hepatitis-C virus is estimated to be 160 million people across all continents. Focusing specifically on the major markets: EU, U.S., Canada, Australia, Japan and Brazil, Gilead Sciences, Inc. (NASDAQ:GILD) estimates that there’s a prevalence about 12.6 million patients around the world, of which only about 36% are currently diagnosed and 4% currently in treatment.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!